About Siolta Therapeutics
Siolta Therapeutics is a company based in San Francisco (United States) founded in 2016 by Nikole Kimes.. Siolta Therapeutics has raised $42 million across 4 funding rounds from investors including Khosla Ventures, HHS and SymBiosis. Siolta Therapeutics offers products and services including Live Biotherapeutics and Precision Symbiotics Platform. Siolta Therapeutics operates in a competitive market with competitors including Biogen, LEO Pharma, UCB, Incyte and Grifols, among others.
- Headquarter San Francisco, United States
- Founders Nikole Kimes
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$42 M (USD)
in 4 rounds
-
Latest Funding Round
$12 M (USD), Series C
Mar 12, 2024
-
Investors
Khosla Ventures
& 6 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Siolta Therapeutics
Siolta Therapeutics offers a comprehensive portfolio of products and services, including Live Biotherapeutics and Precision Symbiotics Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatments targeting diseases through human microbiome modulation.
Tool for designing bacterial combinations for medical applications.
Unlock access to complete
Unlock access to complete
Funding Insights of Siolta Therapeutics
Siolta Therapeutics has successfully raised a total of $42M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $12 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series C — $12.0M
-
First Round
First Round
(22 Sep 2020)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2024 | Amount | Series C - Siolta Therapeutics | Valuation | SymBiosis , Khosla Ventures | |
| Aug, 2023 | Amount | Grant - Siolta Therapeutics | Valuation |
investors |
|
| Feb, 2022 | Amount | Grant - Siolta Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Siolta Therapeutics
Siolta Therapeutics has secured backing from 7 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Khosla Ventures, HHS and SymBiosis. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in healthcare companies are made by SymBiosis.
|
Founded Year | Domain | Location | |
|
Early-stage startups are funded by this venture capital firm.
|
Founded Year | Domain | Location | |
|
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Siolta Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Siolta Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Siolta Therapeutics Comparisons
Competitors of Siolta Therapeutics
Siolta Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, LEO Pharma, UCB, Incyte and Grifols, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating dermatology diseases
|
|
| domain | founded_year | HQ Location |
Therapies for immunological and neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Plasma-derived therapies are developed to treat multiple diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule protein degraders are developed for various disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Siolta Therapeutics
Frequently Asked Questions about Siolta Therapeutics
When was Siolta Therapeutics founded?
Siolta Therapeutics was founded in 2016 and raised its 1st funding round 4 years after it was founded.
Where is Siolta Therapeutics located?
Siolta Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Siolta Therapeutics?
Nikole Kimes is the current CEO of Siolta Therapeutics. They have also founded this company.
Is Siolta Therapeutics a funded company?
Siolta Therapeutics is a funded company, having raised a total of $42M across 4 funding rounds to date. The company's 1st funding round was a Grant of $2.92M, raised on Sep 22, 2020.
What does Siolta Therapeutics do?
Founded in 2016 and based in San Francisco, United States, microbiome therapeutics are developed by the company for the prevention and treatment of chronic inflammatory diseases, with an initial focus on allergic conditions. Targeted products, including the flagship STMC-103H, are advanced for atopic dermatitis, food allergy, and allergic asthma. Operations center on human microbiome research within the biotechnology sector.
Who are the top competitors of Siolta Therapeutics?
Siolta Therapeutics's top competitors include LEO Pharma, Generate Biomedicines and Formation Bio.
What products or services does Siolta Therapeutics offer?
Siolta Therapeutics offers Live Biotherapeutics and Precision Symbiotics Platform.
Who are Siolta Therapeutics's investors?
Siolta Therapeutics has 7 investors. Key investors include Khosla Ventures, HHS, SymBiosis, Seventure Partners, and Global Brain.